As Assistant Director of the Drug Dynamics Institute (DDI), Alan works with development-focused pharmaceutical researchers in academia and industry in advancing drug products through the preclinical stage. Projects range from early stage physicochemical characterization to in vivo efficacy and safety. Specific emphasis has been placed on development and testing of inhaled formulations including initial aerosol characterization, preclinical efficacy models, and GLP inhaled toxicity. Alan also oversees the UTech Dorm Room wet lab incubator space located within the College of Pharmacy. This collaborative effort between DDI and the Austin Technology Incubator (ATI) was formed to provide a wet-lab infrastructure supportive of local biotech start-ups and life science entrepreneurs.
Improving Bioavailability of Poorly Water Soluble Drugs – It is commonly cited that nearly 40% of new compounds identified for therapeutic use exhibit poor aqueous solubility. Many techniques have been used to improve water solubility including particle size reduction, solid dispersion processes, molecular complexation, and self emulsifying systems. Of particular interest is the stabilization of amorphous drug in a suitable pharmaceutical carrier to improve drug solubility and, ultimately, bioavailability.
Efficacy Studies in Preclinical Models of Airway Disease – Prior to conducting clinical trials for a new inhaled therapy, the drug product must be proven efficacious in one or more animal models. New treatments for airway disease are typically evaluated in a sensitized rodent model that will exhibit pulmonary inflammation and constriction similar to that encountered in asthma and COPD. A better understanding of the effects of novel formulations, methods of dose administration, sensitization, and response quantification are needed in these models.
Pharmacotherapy to Prolong Allograft Survival in Transplant Recipients – Following organ transplant, patients are prescribed a multi-drug regimen consisting of immunosuppressive drugs such as corticosteroids, calcineurin inhibitors, and antimetabolites. These transplant therapies are often complicated by opportunistic infection and reduction in patient quality of life due to untoward side effects. Advanced drug formulation and delivery to localize therapy and reduce side effects shows potential to improve outcomes of lung transplant recipients.
> Drug Dynamics Institute
College of Pharmacy
The University of Texas
2409 University Ave.
Austin, TX, USA
Email Address: pharmacy
Enhancing drug-delivery technologies can help in curing and treating diseases such as cancer, cardiovascular diseases, diabetes, fungal, respiratory and infectious diseases and treatment after organ transplants to prevent rejection.